Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

Rhea-AI Summary

Cadrenal Therapeutics, trading under the ticker CVKD, will present at the Emerging Growth Conference on June 12, 2024. The company's management will deliver a webcasted presentation at 10:50 am ET, focusing on their lead product, tecarfarin, a new-generation Vitamin K Antagonist designed to prevent cardiovascular incidents. Attendees can join the live session or access an archived version later. Additionally, the company will hold one-on-one investor meetings post-conference. For meeting requests, attendees can contact the Emerging Growth Conference representative or email Cadrenal's investor relations team.

Positive

• Cadrenal Therapeutics' participation in a prominent conference likely increases investor visibility and interest.
• The presentation will focus on tecarfarin, highlighting its potential to prevent serious cardiovascular events.
• Availability of live and archived webcasts ensures wider accessibility to the company's presentation.

Negative

• The press release lacks specific updates on tecarfarin's clinical progress or financial performance.
• No new financial data or partnership announcements, which may leave investors seeking more concrete information.
• Potential investor dilution if new funding rounds are implied but not disclosed.

PONTE VEDRA, Fla., June 11, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today announced that the Company will be participating in the Emerging Growth Conference on June 12, 2024.

Management will deliver a webcasted presentation and subsequently open the floor to questions during the Conference. Cadrenal's presentation will be on Wednesday, June 12, 2024, at 10:50 am ET. A webcast link of the presentation can be found on the investor relations page of the Company's website or accessed HERE.

If attendees are not able to join the event live on the day of the Conference, an archived webcast will also be made available on www.EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.   

Management will also host one-on-one investor meetings after the Conference. To request a virtual one-on-one meeting with the Company's management team, please contact your respective Emerging Growth Conference representative or email the Company's investor relations team at CVKD@LythamPartners.com.

ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal Therapeutics is developing tecarfarin for unmet needs in anticoagulation therapy. Tecarfarin is a new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions who require lifelong anticoagulation. Tecarfarin has orphan drug designation from the FDA for the prevention of thrombosis and thromboembolism (blood clots) in patients with an implanted mechanical circulatory support device, which includes the left ventricular assist device (LVAD). Tecarfarin also has orphan drug and fast-track designations from the FDA for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib). Tecarfarin is specifically designed to use a different metabolism pathway than the oldest and most commonly prescribed VKA warfarin. Tecarfarin has been evaluated in eleven (11) human clinical trials and more than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients with chronic kidney disease. For more information, please visit: www.cadrenal.com.  

For more information, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com 

Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-present-at-the-emerging-growth-conference-on-june-12-2024-302169889.html

SOURCE Cadrenal Therapeutics, Inc.

FAQ

When is Cadrenal Therapeutics presenting at the Emerging Growth Conference?

Cadrenal Therapeutics will present on June 12, 2024, at 10:50 am ET.

How can I access Cadrenal Therapeutics' presentation at the Emerging Growth Conference?

You can access the presentation live via a webcast link on the company's investor relations page or watch an archived version later.

What is Cadrenal Therapeutics' stock symbol?

The stock symbol for Cadrenal Therapeutics is CVKD.

What product will Cadrenal Therapeutics discuss at the Emerging Growth Conference?

Cadrenal Therapeutics will discuss tecarfarin, a late-stage, new-generation Vitamin K Antagonist.

How can I request a one-on-one meeting with Cadrenal Therapeutics' management?

You can request a one-on-one meeting by contacting the Emerging Growth Conference representative or emailing CVKD's investor relations team at CVKD@LythamPartners.com.